Cargando…

Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole

Chagas disease remains a major social and public health problem in Latin America. Benznidazole (BZN) is the main drug with activity against Trypanosoma cruzi. Due to the high number of adverse drug reactions (ADRs), BZN is underprescribed. The goal of this study was to evaluate the genetic and trans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franco, Lucas A. M., Moreira, Carlos H. V., Buss, Lewis F., Oliveira, Lea C., Martins, Roberta C. R., Manuli, Erika R., Lindoso, José A. L., Busch, Michael P., Pereira, Alexandre C., Sabino, Ester C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920452/ https://www.ncbi.nlm.nih.gov/pubmed/33669428 http://dx.doi.org/10.3390/ijms22041960

Ejemplares similares

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display
por: Rodriguez Carnero, Luis Antonio, et al.
Publicado: (2023)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease
por: Francisco, Amanda Fortes, et al.
Publicado: (2018)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2021)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease
por: Sesti-Costa, Renata, et al.
Publicado: (2014)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy
por: Silva Grijó Farani, Priscila, et al.
Publicado: (2023)

Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease
por: Cevey, Ágata C., et al.
Publicado: (2017)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
por: Mazzeti, Ana Lia, et al.
Publicado: (2023)

Benznidazole
por: Soares-Sobrinho, José Lamartine, et al.
Publicado: (2008)

Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening
por: Perez-Zetune, Victoria, et al.
Publicado: (2020)

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study
por: Hasslocher-Moreno, Alejandro M., et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis
por: Crespillo-Andújar, Clara, et al.
Publicado: (2022)

Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis
por: de Souza-Basqueira, Marcela, et al.
Publicado: (2020)

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
por: Castro Eiro, Melisa D., et al.
Publicado: (2022)

Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)

Clinical Follow-Up of Responses to Treatment with Benznidazol in Amazon: A Cohort Study of Acute Chagas Disease
por: Pinto, Ana Yecê das Neves, et al.
Publicado: (2013)

Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil
por: Rossi Neto, Joao Manoel, et al.
Publicado: (2020)

Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
por: de Oliveira-Silva, Jaquelline Carla Valamiel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hq3l2of69u0jq0cmmpco44c4lk